How to treat breast cancer metastasis

No matter what kind of cancer it is, if it metastasizes, it is in the late stage. It is more difficult to treat cancer at this time. So do you know what to do if breast cancer metastasizes? What to do if breast cancer metastasizes to the lungs? Let us learn about it together.

Once distant metastasis of breast cancer is found, the median survival period is 2 years, but many breast cancer patients can live for several years or even ten years. In recurrent cancer, the time to recurrence is longer and the prognosis is better.

Although distant recurrence after surgery and distant metastasis at the time of clinical diagnosis are different in nature, their prognoses are the same. A survey of 450 breast cancer patients found that the median survival time of patients with soft tissue and bone metastasis was 22 to 26 months, that of patients with lung and pleural metastasis was 10 to 12 months, and that of patients with liver and brain metastasis was 4 to 6 months.

As can be seen, once metastasis occurs, it is rarely cured and the prognosis is poor. Existing treatments can still control it, but they cannot prolong the patient's life and can only allow the patient to live a symptom-free life.

The current treatment is mainly surgery, which is done after surgery to reduce the possibility of recurrence and metastasis and to kill the survival of cancer cells. Radiotherapy and chemotherapy are required after surgery. This is also a case of not understanding what a radical surgery is and how to do radiotherapy and chemotherapy after surgery.

This is because the possibility of tumor recurrence and metastasis is very high. Tumor metastasis mainly occurs through blood metastasis, lymphatic metastasis, implantation metastasis, etc. Tumor metastasis depends on tumor angiogenesis and lymphatic vessels. As long as the formation of tumor angiogenesis and lymphatic vessels can be inhibited, the possibility of metastasis can be reduced.

Ginsenoside Rh2 can inhibit the formation of new blood vessels and lymphatic vessels in tumors, and reduce the possibility of tumor metastasis. Tumor recurrence and metastasis are related to tumor tissue link proteins. This is also mentioned in the literature "Effects of Ginsenoside Rh2 on Transplanted Tumor Growth and Expression of Intercellular Junction Adhesion Molecules".

The JAM family includes three subtypes, namely JAM-1, JAM-2 and JAM-3. JAM is an intercellular junction protein and an important component of the junction complex between endothelial cells. It participates in and mediates the adhesion between cells of the same type. Studies have found that in normal tissues, it is often found in vascular beds and areas rich in lymphatic vessels.

Therefore, Jam is involved in and mediates the adhesion between cancer cells. When cell junctions are damaged, the expression of Jam will inevitably weaken, and the tight junctions between cells will be disconnected, resulting in the scattered cancer cells around the tumor, providing a prerequisite for tumor metastasis.